Compare Franco-Nevada Corporation (FNV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Novartis AG — how do they compare? Franco-Nevada Corporation trades at $233.84 (market cap $46.80B), while Novartis AG trades at $148.12 (market cap $271.82B). The key difference: Novartis AG is far larger — about 5.8× Franco-Nevada Corporation's market cap, and Novartis AG pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Novartis AG for 82 Days on average.
| FNV | NVS | |
|---|---|---|
Market Cap | $46.80B | $271.82B |
Volume | 310,692 | 1,841,354 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $168.62 |
52-Week Low | $183.97 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $45.79B | $313.15B |
Dividend Yield | 0.72% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
NVS trades at $146.88, up 2.11% today, with a bearish technical signal from moving averages and an overbought RSI. The company reported revenue of $56.67B in 2025, with a net income margin of 22.5%, and recently announced a $7.8B licensing deal with China's Abogen for RNA-based therapy. Earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026.
The outlook is cautious due to recent clinical trial setbacks and investor scrutiny of M&A strategy. Analyst consensus is a $146 price target with a hold-heavy rating. Risks include pipeline failures and competitive pressures, but strong cash flow and profitability provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
